AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03322774 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Hygiene Education Control
Description: Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
Study NCT00733551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
Study NCT00733551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
Study NCT02186496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 8/5mg
Study NCT02186496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 8mg and Amlodipine 5mg
Study NCT03134937 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)
Description: Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
Study NCT04402021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor Walking
Description: Unsupervised outdoor walking will be the mode used for moderate-intensity aerobic exercise. The walking intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
Study NCT04402021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quiet Rest
Description: The quiet rest condition will consist of watching a nature documentary in a quiet room. The quiet rest intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
Study NCT03696732 — intervention group
Intervention type: OTHER
Intervention: Anxiety questionnaire
Description: Spielberger. State-Trait Inventory questionnaire
Study NCT03696732 — intervention group
Intervention type: OTHER
Intervention: VAS questionnaire
Description: verbal numerical scale (VNS) anxiety score
Study NCT01405521 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine placebo (excipients only)
Description: single oral dose,
Study NCT01405521 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ty21a
Description: 3 oral doses, alternate days
Study NCT01405521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M10ZH09 vaccine
Description: single oral dose
Study NCT00676429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone Hydrochloride
Description: Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
Study NCT00676429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as oral solution, individually titrated
Study NCT03229356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practices Advisory (BPA)
Description: 1. BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~2. Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement.
Study NCT03229356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BPA + Enhanced Education
Description: BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
Study NCT01745718 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cytological imprints
Description: Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
Study NCT02588651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: study drug given intravenously to determine efficacy in study diseases
Study NCT04159415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
Study NCT04159415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose REGN4461
Description: IV infusion loading dose or SC injection QW.
Study NCT04159415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose REGN4461
Description: IV infusion loading dose or SC injection QW.
Study NCT03257852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5094
Description: intravenously administration
Study NCT03257852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously administration
Study NCT03257852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methotrexate therapy
Description: MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
Study NCT03257852 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate therapy
Description: MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
Study NCT03990571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT03990571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO
Study NCT04233567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Given PO
Study NCT01391195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy by low level laser therapy
Description: Phototherapy by low level laser therapy during 9 weeks
Study NCT03677882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Body Bridging Group Session
Description: Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
Study NCT02969031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced SCOPE training
Description: Intervention is integrated into the American Board of Internal Medicine (ABIM) Maintenance Of Certification (MOC) process.
Study NCT02969031 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Communication training
Description: Standard Communication training
Study NCT03572855 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Scoliosis Brace
Description: Brace will be fitted to each subject by a spine orthopedic surgeon before the testing. The subject will wear the fitted brace for 2 months.
Study NCT02409303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen-Refer-Treat Intervention
Description: This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
Study NCT03777865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: All subjects receive a single dose (0.5mL) of 13vPnC
Study NCT02611830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg IV
Description: Vedolizumab intravenous infusion
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denintuzumab mafodotin
Description: SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
Study NCT02611830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Vedolizumab intravenous infusion placebo
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study NCT02611830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 108 mg SC
Description: Vedolizumab subcutaneous injection
Study NCT02611830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Vedolizumab subcutaneous injection placebo
Study NCT02800603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check Up
Description: The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings.
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study NCT02798029 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Frameless Fractionated Stereotactic Radiation Therapy
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
Study NCT02855359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
Study NCT01482143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study NCT01773161 — intervention group
Intervention type: PROCEDURE
Intervention: Cerebral palsy, post hip surgery
Description: All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
Study NCT01068210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (\~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (\~70%-100% VO2peak / \~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
Study NCT01068210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Stretching
Description: The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
Study NCT02567734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-guided percutaneous irreversible electroporation
Description: Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
Study NCT02657057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTNS
Description: The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
Study NCT02657057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS SNS
Description: Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
Study NCT03465774 — intervention group
Intervention type: DRUG
Intervention: Doxycycline
Description: Receive via IPC
Study NCT03465774 — intervention group
Intervention type: DEVICE
Intervention: Indwelling Catheter
Description: Receive IPC
Study NCT03465774 — intervention group
Intervention type: PROCEDURE
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03465774 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03465774 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03155178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep
Description: Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
Study NCT03155178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
Study NCT02548351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Study NCT02548351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03098498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival Debridement
Description: Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions
Study NCT03098498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgingival Debridement
Description: Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions
Study NCT03329170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention using motivational interviewing
Description: A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is \<12 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
Study NCT03250390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of volatile organic compounds during exhalation
Description: The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)
Study NCT03250390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collection of volatile organic compounds during exhalation
Description: The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)
Study NCT01005823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 29102 cream
Description: Twice daily application for 7 days
Study NCT01005823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 29102 placebo cream
Description: LEO 29102 placebo cream
Study NCT02118142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betaine
Description: 6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage
Study NCT02118142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: 6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage
Study NCT01790828 — intervention group
Intervention type: DRUG
Intervention: Xyntha : coagulation factor IIIV (recombinant)
Description: Xyntha will be administered according to physician's discretion.
Study NCT03185754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sublobar resection
Description: Sublobar resection
Study NCT03185754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lobectomy
Description: lobectomy
Study NCT04139512 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: guided surgery
Description: placement of implant with local anesthesia using full guided surgery protocol versus free- hande one
Study NCT04139512 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventionnel implant placement
Description: placement of dental implant with conventionnal freehand technic
Study NCT03069599 — intervention group
Intervention type: PROCEDURE
Intervention: irreversible electroporation (IRE)
Description: Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
Study NCT04190511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic-containing dairy
Description: The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition. On this basis, intervention was carried out using prebiotic-containing dairy products (200g/day).
Study NCT04190511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.
Study NCT04190511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.
Study NCT04216693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.